Search hospitals > Maryland > Columbia
Maryland Oncology Hematology, PA
Claim this profileColumbia, Maryland 21044
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Prostate Cancer
69 reported clinical trials
5 medical researchers
Summary
Maryland Oncology Hematology, PA is a medical facility located in Columbia, Maryland. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Cancer, Prostate Cancer and other specialties. Maryland Oncology Hematology, PA is involved with conducting 69 clinical trials across 86 conditions. There are 5 research doctors associated with this hospital, such as Kashif Ali, Mohit Narang, MD, Yousuf Gaffar, MD, and Cheryl A Aylesworth.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
HER2 positive
Stage IV
2Non-Small Cell Lung Cancer
Global LeaderStage IV
RET
Stage III
Top PIs
Kashif AliMaryland Oncology Hematology1 year of reported clinical research
Studies Tumors
Studies Lung Cancer
8 reported clinical trials
16 drugs studied
Mohit Narang, MDMaryland Oncology Hematology, P.A3 years of reported clinical research
Studies Adenocarcinoma
Studies Pancreatic Adenocarcinoma
4 reported clinical trials
12 drugs studied
Yousuf Gaffar, MDMaryland Oncology Hematology, P.A.3 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
3 reported clinical trials
8 drugs studied
Cheryl A AylesworthMaryland Oncology Hematology, P.A.3 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
3 reported clinical trials
9 drugs studied
Clinical Trials running at Maryland Oncology Hematology, PA
Multiple Myeloma
Mantle Cell Lymphoma
Plasma Cell Neoplasms
Lymphoma
Follicular Lymphoma
Pancreatic Cancer
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Myelofibrosis
Teclistamab
for Multiple Myeloma
This trial is testing Teclistamab, a drug that helps the immune system fight a type of blood cancer in adults who haven't responded to other treatments. It works by connecting immune cells to cancer cells, making it easier for the body to attack the cancer. Teclistamab shows promise in multiple myeloma treatment.
Recruiting1 award Phase 215 criteria
BGB-11417 + Dexamethasone + Carfilzomib
for Multiple Myeloma
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.
Recruiting1 award Phase 1 & 29 criteria
Selinexor + DRd
for Multiple Myeloma
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Recruiting1 award Phase 29 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Maryland Oncology Hematology, PA?
Maryland Oncology Hematology, PA is a medical facility located in Columbia, Maryland. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Cancer, Prostate Cancer and other specialties. Maryland Oncology Hematology, PA is involved with conducting 69 clinical trials across 86 conditions. There are 5 research doctors associated with this hospital, such as Kashif Ali, Mohit Narang, MD, Yousuf Gaffar, MD, and Cheryl A Aylesworth.